Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Observer-blind, Active-controlled Study to Describe the Safety of Recombinant Acellular Pertussis (aP) Vaccine When Administered to Healthy Adults Aged of 18-75 Years Old

NCT06798831 is registered in ClinicalTrials.gov with BioNet-Asia Co., Ltd. as lead sponsor.

NCT NCT06798831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06798831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Observer-blind, Active-controlled Study to Describe the Safety of Recombinant Acellular Pertussis (aP) Vaccine When Administered to Healthy Adults Aged of 18-75 Years Old
Lead sponsor
BioNet-Asia Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 8, 2025
Completion date
October 31, 2025
Enrollment
2,399 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pertussis vaccine